January 23, 2025
Neomorph Secures Third Major Collaboration with AbbVie for Molecular Glue Degraders Worth Up to $1.64 Billion
Neomorph, AbbVie, molecular glue degraders, protein degradation, oncology, immunology, biotechnology, pharmaceutical collaboration
Chinese Vaccine Biotech Ab&B Files for IPO, Drawing Attention from GSK, Merck, and Pfizer
Ab&B Bio-Tech, IPO, Chinese vaccine biotech, GSK, Merck, Pfizer, biotechnology, pharmaceutical industry
FDA Adds Boxed Warning to Teva’s Copaxone and Generic Glatopa Due to Anaphylaxis Risk
FDA Boxed Warning, Anaphylaxis Risk, Copaxone, Glatopa, Glatiramer Acetate, Multiple Sclerosis (MS) Treatment, Allergic Reaction
Revitalizing Maternal Health: Nonprofit Leverages Low-Dose Aspirin to Combat Preeclampsia Disparities
Preeclampsia, Maternal Health Equity, Low-Dose Aspirin, GAP—SPIRIN, Health Disparities, Black Maternal Health
Catalent and Galapagos Collaborate on Decentralized CAR-T Manufacturing; Kindeva Secures $129M Contract for Nerve Agent Antidote
Catalent, Galapagos, CAR-T therapy, Decentralized manufacturing, Non-Hodgkin lymphoma (NHL), Kindeva Drug Delivery, DuoDote, Nerve agent antidote, Strategic National Stockpile
Samsung Biologics Achieves Record Revenue and Secures Largest Contract to Date
Samsung Biologics, Record Revenue, Largest Contract, Biosimilars, CDMO, Pharmaceutical Industry
Chinese Biotechs Flock to Hong Kong IPOs for Next Growth Phase
Chinese biotechs, Hong Kong IPOs, biotechnology, pharmaceuticals, listing reforms, HKEX, Chapter 18A, biotech listings, Greater Bay Area.
Tris Pharma’s Cebranopadol Shows Promising Results in Phase 3 Trial for Moderate-to-Severe Acute Pain Treatment
Cebranopadol, Tris Pharma, ALLEVIATE-1, Phase 3 Clinical Trial, Acute Pain Treatment, Dual-NMR Agonist, Opioid Crisis, Pain Management
Xilio Therapeutics Stock Plunges Following Initial Phase 2 Data for Vilastobart in Colorectal Cancer Treatment
Xilio Therapeutics, Vilastobart, Anti-CTLA-4, Colorectal Cancer, Stock Price, Phase 2 Data
Biogen’s Strategic Pivot: Emphasizing External Collaborations and Diversification
Biogen, research strategy, external collaborations, diversification, Alzheimer’s disease, rare diseases, immunology, neuroscience, neurodegeneration